Amarin's position is stronger...
ILT, vehemently disagree. The entire strategy of the company (GIA in US, partnership/license EU/ROW) has been flipped. With the patent reversal, the foundation to build value (US sales) is considered at risk, subject to litigation. As a result, their ability to leverage assets elsewhere (partnership/license EU/ROW) has been substantially weakened.